<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160220</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT05160220</nct_id>
  </id_info>
  <brief_title>Naturalistic Study of Microdosing With Psilocybin</brief_title>
  <acronym>NATMICRO</acronym>
  <official_title>Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Council of Scientific and Technical Research, Argentina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Council of Scientific and Technical Research, Argentina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to understand the neural, cognitive and behavioral effects of low doses of&#xD;
      psilocybin administered in the form of dried mushroom material (0.5 g of Psilocybe cubensis)&#xD;
      consumed in natural settings following a placebo-controlled double-blind experimental design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sub-threshold doses of serotonergic psychedelics are frequently consumed as cognitive&#xD;
      enhancers, and due to their purported positive effects on mood, energy and creativity&#xD;
      (&quot;microdosing&quot;).&#xD;
&#xD;
      The acute and short-term effects of psilocybin (the psychoactive compound of Psilocybe&#xD;
      cubensis mushrooms) on several variables will be investigated, comprising spontaneous and&#xD;
      evoked electrophysiological brain activity, perception and cognitive function (cognitive&#xD;
      flexibility, attention, inhibitory control, conscious access, visual perception), creativity&#xD;
      (problem solving, divergent and convergent thinking), behavior (actigraphy and sleep&#xD;
      patterns, natural language production) and several domains related to well-being and mental&#xD;
      health of the participants.&#xD;
&#xD;
      This study is simultaneously naturalistic (i.e. recruited subjects are intrinsically&#xD;
      motivated to microdose, as they have decided to embark in a microdosing protocol) and&#xD;
      controlled by expectations, following a double-blind placebo-controlled design. Participants&#xD;
      will microdose according to the following schedule:&#xD;
&#xD;
      Two sessions (0.5 g dried Psilocybin mushrooms vs. dried edible mushroom material without&#xD;
      psychoactive effects as a placebo condition) will be conducted. A third party will be in&#xD;
      charge of generating their active dose and placebo capsules, and they will also implement a&#xD;
      blinding procedure.&#xD;
&#xD;
      Each session will span one week of measurements. Subjects will be given a smartwatch to&#xD;
      monitor activity and sleeping patterns at the beginning of the week. At days 3 and 5,&#xD;
      subjects will take capsules with active mushroom material or placebo, and then several&#xD;
      variables will be recorded. Experiments will be conducted in a setting that is natural and&#xD;
      comfortable for the participants, e.g. their homes.&#xD;
&#xD;
      The main outcome measures consist of resting state activity recorded with EEG, evoked&#xD;
      response potentials and performance during cognitive tasks, behavioral variables obtained&#xD;
      with actigraphy and automated sleep scoring, natural language analysis, and several measurs&#xD;
      self-reported via standarized questionnaires.&#xD;
&#xD;
      After completion, this study will provide direct evidence concerning the efficacy of&#xD;
      microdosing for cognitive enhancement under natural conditions, i.e. those most frequently&#xD;
      used by individuals who microdose, as well as provide information concerning the potential&#xD;
      underlying neurobiological mechanisms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting state oscillations measured with EEG</measure>
    <time_frame>1 week</time_frame>
    <description>Our goal is to study changes in spectral content before and during the acute effects with the purpose of comparing changes with those observed under higher doses of psilocybin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attention</measure>
    <time_frame>1 week</time_frame>
    <description>Measured performance in the attentional blink paradigm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inhibitory control</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the go/no go experimental paradigm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conscious access</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the backward masking paradigm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual perception</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the binocular rivalry paradigm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical activity</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using wrist actigraphy using a smartwach</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Divergent thinking</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the Alternative Uses Task (AUT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attention</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the hiearchical mismatch negativity paradigm combined with EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive flexibility</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the stroop task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Convergent thinking</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the Remote Associations Task (RAT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Convergent thinking</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the Wallach-Kogan test (WK)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect positive/negative affect and well-being</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the Positive and Negative Affect Schedule (PANAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on anxiety</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using State Trait Anxiety Inventory (STAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on personality</measure>
    <time_frame>1 week</time_frame>
    <description>Measured using the Big Five inventory (BFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of psilocybin in the dried material</measure>
    <time_frame>1 week</time_frame>
    <description>To be measured using high performance liquid chromatography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Cognitive Change</condition>
  <condition>Creativity</condition>
  <condition>Mood Change</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Psilocybe cubensis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 g dried and powdered P. cubensis in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same weight of inactive placebo in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.</description>
    <arm_group_label>Psilocybe cubensis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 g dried edible non-psychoactive mushroom material.</description>
    <arm_group_label>Inactive placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and woman with more than 21 years.&#xD;
&#xD;
          2. Participans are planning to microdose using their own dried mushroom material and&#xD;
             adhere to the experimental protocol.&#xD;
&#xD;
          3. No active psychiatric conditions requiring treatment with psychotropic medications.&#xD;
&#xD;
          4. Able to provide informed consent.&#xD;
&#xD;
        Excusion Criteria:&#xD;
&#xD;
          1. Use of psychotropic medication during the study, including stimulants such as&#xD;
             caffeine.&#xD;
&#xD;
          2. Prior adverse reactions to psychedelics according to the Challenging Experiences&#xD;
             Questionnaire administered during initial screening.&#xD;
&#xD;
          3. Pregnant women or women during lactation&#xD;
&#xD;
          4. History of high or low blood pressure or other cardiovascular risks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enzo Tagliazucchi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Council of Scientific and Technical Research, Argentina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Fisica de Buenos Aires (IFIBA)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Council of Scientific and Technical Research, Argentina</investigator_affiliation>
    <investigator_full_name>Enzo Tagliazucchi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>psilocybin</keyword>
  <keyword>psychedelics</keyword>
  <keyword>nootropics</keyword>
  <keyword>microdosing</keyword>
  <keyword>EEG</keyword>
  <keyword>cognition</keyword>
  <keyword>creativity</keyword>
  <keyword>behavior</keyword>
  <keyword>sleep</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All raw data will be made available online through a data sharing webside (e.g. Zenodo) upon publication of the pre-pring containing the results of our study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After publication, indefinite.</ipd_time_frame>
    <ipd_access_criteria>Public</ipd_access_criteria>
    <ipd_url>https://zenodo.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

